Zacks: Evelo Biosciences Inc (EVLO) Receives Average Rating of “Strong Buy” from Brokerages

Evelo Biosciences Inc (NASDAQ:EVLO) has been given an average broker rating score of 1.13 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.

Analysts have set a 1-year consensus price target of $27.00 for the company, according to Zacks. Zacks has also assigned Evelo Biosciences an industry rank of 91 out of 255 based on the ratings given to its competitors.

Separately, Morgan Stanley raised their price objective on shares of Evelo Biosciences from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp purchased a new stake in Evelo Biosciences in the second quarter worth about $165,000. Northern Trust Corp purchased a new stake in Evelo Biosciences in the second quarter worth about $227,000. Schwab Charles Investment Management Inc. purchased a new stake in Evelo Biosciences in the second quarter worth about $267,000. Essex Investment Management Co. LLC purchased a new stake in Evelo Biosciences in the second quarter worth about $271,000. Finally, Jane Street Group LLC purchased a new stake in Evelo Biosciences in the second quarter worth about $316,000. Institutional investors and hedge funds own 80.51% of the company’s stock.

NASDAQ EVLO opened at $9.81 on Thursday. The company has a current ratio of 24.08, a quick ratio of 24.08 and a debt-to-equity ratio of 0.09. Evelo Biosciences has a 1 year low of $9.29 and a 1 year high of $16.75.

Evelo Biosciences (NASDAQ:EVLO) last issued its quarterly earnings data on Thursday, August 2nd. The company reported ($0.85) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.49). On average, equities analysts predict that Evelo Biosciences will post -1.88 earnings per share for the current fiscal year.

About Evelo Biosciences

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types.

Further Reading: What are retained earnings?

Get a free copy of the Zacks research report on Evelo Biosciences (EVLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply